Gerald Clarke | 10/02/2013
For Dr Hella Kohlhof, the study of epigenetics was not love at first sight, however the potential it posesses eventually won her over. Now Dr Kohlhof is Manager of Translational Pharmacology at 4SC AG and is applying epigenetic knowledge in a phase 1 first-in-man trial. She talks to us about what role epigentics plays in cancer and how new therapies are taking advantage of epigenetic mechanisms.
To continue reading this story Click Here
Upcoming Events
AI for Pharma & Healthcare
23 - 25 September, 2025
Amsterdam
Register Now |
View Agenda |
Learn More